
The Johnson & Johnson-owned Danish company Janssen-Cilag emerged from 2011 with a moderate growth, as turnover rose 0.7 % from DKK 279 to 281 million in 2011.
The company attributes the growth to the launch of a number of new products and general growth within the markets for HIV and Psoriasis, which has compensated for losses due to patent expirations. Janssen-Cilag describes the result as satisfactory.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app